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Abstract
Background: Alternative treatments are commonly used for various disorders and often taken
on-demand. On-demand treatment of gastroesophageal reflux disease (GERD) with pharmaceutical
products is an established, cost-effective strategy. Comparisons between alternative medicine and
pharmaceutical products are rare. The aim of this trial was to compare on-demand treatment with
a pectin-based, raft-forming, natural, anti-reflux agent (PRA) with that of esomeprazole 20 mg
(Eso20) in patients with mild/moderate GERD.
Methods: Patients with mild/moderate GERD were randomised to a six weeks' on-demand
treatment with PRA or Eso20 in a pragmatic, open, multicentre trial. Overall satisfaction with
treatment, satisfactory relief on a weekly basis, reflux symptoms, and treatment preferences were
noted.
Results: Seventy-seven patients were included in the analyses. Eso20 was significantly superior to
PRA for proportion of overall satisfied patients (92% and 58% respectively; p = 0.001), reduction
of symptoms (mean symptom scores at the end 5.9 and 8.0 respectively; p = 0.019), proportion of
weeks of satisfactory relief (89% and 62% respectively; p = 0.008) and proportion preferring
continuation with the same treatment (85% and 42% respectively; p < 0.001). Older patients were
more satisfied than younger, and patients preferring on-demand treatment had lower symptom
scores at inclusion than those preferring regular treatment.
Conclusion: On-demand treatment with esomeprazole 20 mg was clearly superior to the pectin-
based raft-forming agent. Most patients preferred on-demand treatment to regular treatment.
Those preferring regular therapy had significantly more symptoms at inclusion.
Trial registration: ClinicalTrials.gov: NCT00184522.
Background
On-demand treatment of mild/moderate gastroesopha-
geal reflux disease is an effective and cost-reducing strat-
egy for long-term management [1-4]. The goal of reflux
treatment is not necessarily complete absence of symp-
toms and normalisation of minor endothelial lesions, but
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satisfactory relief of symptoms, healing of major esopha-
geal lesions and prevention of complications [5]. If an
effective, fast-acting and sufficient long-lasting therapy is
easily at hand, the patients seem to accept some intermit-
tent complaints and on their own chose on-demand treat-
ment [6-8]. There is an increasing use of complementary
and alternative medicine (CAM) that, in contrast to drugs,
is believed to be harmless. These products are often used
on-demand.
On-demand treatment with esomeprazole has a well-doc-
umented effect in placebo-controlled trials [1,5] It is,
however, probably not the ideal drug for on-demand
treatment because the onset of action is delayed and max-
imal effect appears after several doses. CAM is preferred by
many patients and deserves attention and comparisons
with pharmaceutical products. Aflurax® (Ferrosan AS) is a
pectin-based, raft-forming natural agent approved for sale
over the counter for mild/moderate reflux symptoms [9-
12]. It has been marketed as an innocent, natural, pectin-
based, locally acting, non-absorbable product with a rapid
onset of effect, and is preferred by many patients, espe-
cially pregnant women.
On-demand treatment is an established administration
schedule, but there are few comparisons between on-
demand treatment with different drugs and little informa-
tion about the characteristics of patients preferring this
dosage schedule.
This open randomised controlled trial compared the
symptomatic effect of on-demand treatment with a pec-
tin-based, raft-forming, natural, anti-reflux agent with
that of esomeprazole (Nexium® AstraZeneca) 20 mg, and
studied patient satisfaction with the products and the
administration schedule.
Methods
Subjects
Nine outpatient clinics included consecutive patients
above 18 years of age with mild/moderate heartburn/
regurgitation as main symptom for more than 3 months
and symptoms at least two days per week the last two
weeks. Mild symptoms were defined as symptoms not
interfering with daily activities, and moderate as symp-
toms interfering with daily activities but not interrupting
or avoiding daily activities. Patients with mild dyspepsia
or irritable bowel syndrome were included if heartburn/
regurgitation clearly was the main complaint. A gastros-
copy was performed and patients with non erosive reflux
disease (NERD) and esophagitis Los Angeles grade A and
B were included. Patients in need of continuous treatment
as judged by the responsible physicians, were excluded, as
were patients who had taken acid secretion inhibitors or
antacids for five or more days the last two weeks, patients
who clearly preferred continuous treatment, patients with
other diseases that could influence the assessment, and
those with anticipated poor compliance or significant
drug or alcohol abuse. Pregnant or breast-feeding women
and fertile women not practising a medically approved
method of contraception were also excluded.
Treatment regimens
The patients were randomized to treatment with one of
the following regimens:
Esomeprazole (Nexium®, Astra-Zeneca) 20 mg tablets
(Eso20) to be taken only when experiencing heartburn/
regurgitation, upward limited to once daily.
A pectin-based, raft-forming, anti-reflux agent (Aflurax®,
Ferrosan) (PRA) given as chewable tablets to be taken
only when experiencing heartburn/regurgitation, upward
limited to eight tablets per day. The product contains mag-
nesium carbonate and potassium bicarbonate that react to
form the raft. The raft acts as a physical barrier to reflux,
or, if reflux occurs, the reflux consists of the raft and not
acidic gastric content [12].
The drugs were taken to relieve symptoms, not to prevent
symptoms, unlike intermittent treatment when drugs are
taken regularly for short periods with symptoms.
Study design
The study was a pragmatic, open, multi centre, block ran-
domized (with variable block size, allocation ratio one,
and stratified for centres and NERD versus esophagitis)
clinical trial with a parallel group design. Randomization
was computer based at the Unit for Applied Clinical
Research, Faculty of Medicine, Norwegian University of
Science and Technology who allocated the patients to one
of the treatment groups after a phone call from the centre.
The study duration was six weeks with visits at inclusion
and at the end.
Variables
At inclusion, all patients had socio-demographic informa-
tion noted, a medical history taken, a physical examina-
tion and gastroscopy with description of esophagitis
according to the Los Angeles classification performed, and
haematological and biochemical tests taken when
needed. Tests for H. pylori and life style modifications
were not part of the study and were performed according
to the doctors' discretion.
The patients filled in a reflux symptom questionnaire at
inclusion and at the end. Five questions regarding reflux
symptoms from the Gastrointestinal Symptom Rating
Scale (GSRS) were scored on a seven point Likert scale
from 0 – 6, giving a symptom score with range 0 – 30 [13].BMC Complementary and Alternative Medicine 2009, 9:3 http://www.biomedcentral.com/1472-6882/9/3
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The patients answered three questions on a diary card at
the end of each treatment week: 1: Have you had heart-
burn/regurgitation the last week (Yes/No)? 2: Have you
taken study drugs the last week (Yes/No)? 3: Did the
intake of drugs result in satisfactory relief of symptoms the
last week (Yes/No)? The proportion of weeks of satisfac-
tory relief of drug treatment was calculated.
At the last visit, unused medication was returned and
counted and the patients were asked for overall satisfac-
tion with the treatment (yes/no), preference for further
drug treatment (continue with the same drug or switch to
another drug), preference for on-demand versus continu-
ous treatment, and side effects. Spontaneously reported
side effects were recorded and the following foreseeable
inconveniences/side effects were asked for (yes/no): Was
the time until effect of the tablets too long? Did the symp-
toms recur too early? Was the number of tablets too high?
Did you have any inconveniences with the intake of the
drug?
Statistics
The analyses were performed with t-test (for variables
with normal distribution), Mann-Whitney U-test, Fisher's
exact test, Chi-square test with linear-by-linear association
when appropriate and logistic regression analyses by
means of the statistical package SPSS® v.13 with exact tests
when available in the package. Two-tailed significance
tests were used and p-values < 0.05 were regarded as sta-
tistically significant.
The main analysis was a modified intention to treat (ITT)
analysis. Missing data were replaced by carrying the last
observation forward or imputation of overall mean if no
previous observations were available. Patients with com-
plete data, i.e. at least four weeks with correctly filled in
diary cards, were included in the per protocol analyses.
The study was designed to show non-inferiority of PRA to
Eso20. Eso20 was presumed to give overall satisfaction in
80% of patients, and non-inferiority was defined as an
effect of PRA that was at most 10% inferior to Eso20. The
number of patients necessary to show this equivalence is
200 in each group (α = 0.05, β = 0.20, one-sided test).
Because an impression arose that PRA was less effective
than Eso20, an interim analysis was performed and the
trial was terminated prematurely. The results are given as
mean and SD if not otherwise indicated.
Ethics
The trial was conducted according to the Declaration of
Helsinki and approved by The Regional Committee for
Medical Research Ethics in Trondheim, Norwegian Social
Science Data Services (NSD) and Norwegian Medicines
Agency (SLV); Norway. All patients got oral and written
information about the trial and gave written informed
consent to participate before inclusion in the trial.
Results
Eighty-two patients were included, 77 were available for
the ITT analyses and 73 for the PP analyses. Figure 1 shows
the flow of patients through the trial. Table 1 gives the
patients' characteristics. There were no significant differ-
ences between the two treatment groups at inclusion.
Fifty-eight patients (75%) were overall satisfied with the
treatment. Table 2 gives the results of the comparisons
between the two treatment groups. Eso20 was signifi-
cantly superior to PRA for overall satisfaction with treat-
ment, number of weeks with satisfactory relief of
symptoms, reduction of symptoms and preference for
continuation with the same treatment. The comparisons
between patients with and without overall satisfaction
with the treatment are shown in table 3. Overall satisfied
patients were significantly older, smoked less, had lower
symptom score at the end and more weeks with satisfac-
tory relief of symptoms. Symptom score at inclusion and
at the end were not correlated with age (r = 0.048; p = 0.68
and r = -0.17; p = 0.13 respectively). Symptom score at
inclusion in patients who at the end preferred regular and
on-demand treatment were 13.8 (4.3) and 10.9 (3.8)
respectively (p = 0.017). There were no other differences
between the groups preferring regular and on-demand
treatment (data not shown). Figure 2 shows symptom
score at the end in different groups of patients. Independ-
ent predictors (logistic regression analyses) for overall sat-
isfaction were: Treatment group (Eso20) (OR = 8.53; 95%
CI: 1.81–40.13; p = 0.007) and older age (OR = 1.066;
95% CI: 1.01–1.12; p = 0.02) with a trend for a relation to
low symptom score at the end (OR = 1.167; 95% CI:
0.988–1.377; p = 0.068) and non smoking (OR = 2.247;
95% CI: 0.941–28.905; p = 0.069). The per protocol anal-
yses showed corresponding results (data not shown).
The mean daily use of Eso20 was 0.59 tablets (95% CI
0.49 – 0.68). Misunderstandings hampered reliable calcu-
lation of the intake of PRA.
Discussion
Esomeprazole was clearly superior to PRA. Patients on
esomeprazole reported a higher prevalence of overall sat-
isfaction with the treatment, had more weeks of satisfac-
tory symptom relief, a lower symptom score the last two
weeks and preferred more often to continue the same
treatment. This superiority of established pharmacologi-
cal treatment over CAM explains the infrequent use of
alternative medicine for reflux disease compared to the
use for other disorders [14]. However, it was not an ideal
treatment. Delayed onset of effect and rapid relapse of
symptoms were noted by one out of four and five patients
respectively. Satisfactory relief of symptoms failed everyBMC Complementary and Alternative Medicine 2009, 9:3 http://www.biomedcentral.com/1472-6882/9/3
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10th week, 15% asked for another drug and 15% preferred
regular treatment.
PRA was less effective, but more than half of the patients
were satisfied with the treatment and nearly half of them
wanted to continue the treatment. The main advantage of
PRA was a trend toward a faster acting effect. Disadvan-
tages were rapid relapse of symptoms, intake of too many
tablets, and some diarrhoea.
The placebo response in mild/moderate reflux disease is
substantial. This study allows no comparisons with pla-
cebo, but PRA is probably more effective than placebo.
Other raft-forming agents have shown an immediate
reduction in gastro-oesophaeal reflux and increase in
oesophageal pH, which is superior to that of omeprazole
for 4 hours [15]. PRA reduces reflux of both food and acid.
The reduced reflux of food and not only acid shows the
rafting properties of PRA, which seem to be at least as
good as those of comparable anti-reflux agents [12]. Two
placebo-controlled clinical trials have proven a sympto-
matic effect of PRA above placebo [9,11]. The placebo
response rates vary a lot in clinical studies but are in most
studies inferior to that of PRA in this study [1,5]. There-
fore, PRA seems to be an alternative for a minority of
patients with mild/moderate reflux disease who prefer
natural, locally acting, non-absorbable agents rather than
ordinary pharmaceutical products.
Evidence Based Medicine has to become involved into
CAM as long as our patients prefer, use and report effects
of such products. We need knowledge, but unlike this
trial, CAM-producers seldom support high quality
research. This study indicates that alternative products
could have a place in the therapeutic armamentarium.
Overall satisfaction was the main outcome in the trial.
This outcome depends on factors like symptomatic effect,
drug administration schedule (e.g. on-demand versus
continuous treatment, or dosing once versus several times
daily) number of tablets, drug formulation (e.g. small or
large tablets, chewable tablets, or granules), taste, prefer-
ence for natural or pharmaceutical products, age, disease
under study, expectation and experience from previous
treatment regimens etc. This study does not allow conclu-
sions about all factors related to overall satisfaction. The
most important predictor for overall satisfaction was treat-
ment with esomeprazole. This is likely due to the efficient
The figure shows the flow of patients through the trial Figure 1
The figure shows the flow of patients through the trial. (Eso20 = Esomeprazole 20; PRA = Pectin-based, raft-forming 
agent; ITT = Intention to treat; PP = Per protocol).
|
Excluded                                             Randomized  Excluded
|
Included
82 patients
Eso 20
42 patients
PRA
40 patients
Regular treatment (no 1)
No symptoms (no 1)
Regular treatment (no 1)
No symptoms (no 1)
Lost to follow up (no 1)
39 
patients
38
patients
ITT analyses
Insufficiently filled in
symptom records (no 1) 
Insufficiently filled in
symptom records (no 3) 
36 
patients
37
patients
PP analyses
|
|
|
|
|
|
|
|
|
|
|
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relief of symptoms, but not only. The convenient dosage
schedule with one tablet a day, the rather long-lasting
effect, the good tolerance and perhaps previous experi-
ence with acid secretion inhibitors might have contrib-
uted to overall satisfaction with esomeprazole. Symptom
score last two weeks showed an insignificant trend toward
prediction of overall satisfaction after correction for treat-
ment group and indicates that symptom relief is not deci-
sive for satisfaction.
Overall satisfaction increased with age. Since symptoms
did not correlate with age, other factors such as habitua-
tion to and tolerance for minor complaints and gratitude
for some symptom relief might increase with age and
explain the increased satisfaction in the elderly.
Patient preference for continuing on-demand treatment
was impressive and in accordance with other studies [6,7].
On-demand treatment will necessarily result in more
symptoms than continuous therapy does, but despite of
more symptoms patients are nearly as satisfied with on-
demand treatment as continuous treatment [8]. Twelve
patients (16%) wanted to switch to regular treatment after
the trial. The perfect drug for on-demand treatment has an
immediate, long-lasting and sufficient effect [16], which is
not fulfilled by any of the actual drugs. A high symptom
The box plot shows the reflux symptom scores (10th, 25th, 50th, 75th and 90th percentiles and outlying values) at the end of the  study related to treatment group, overall satisfaction and preference for regular treatment Figure 2
The box plot shows the reflux symptom scores (10th, 25th, 50th, 75th and 90th percentiles and outlying values) at 
the end of the study related to treatment group, overall satisfaction and preference for regular treatment. 
(Eso20 = Esomeprazole 20 mg; PRA = Pectin-based, raft-forming agent).
	

 

 

Ō
 
 ō Ō
 
!ōŌ
 

 
"#$ ōBMC Complementary and Alternative Medicine 2009, 9:3 http://www.biomedcentral.com/1472-6882/9/3
Page 6 of 8
(page number not for citation purposes)
score at inclusion was the only predictor for continuous
treatment, not the degree of symptoms at the end. Even
with an ideal drug, it is likely that on-demand treatment
is unacceptable for some patients since it implies relapses.
Continuous treatment is probably preferable especially if
symptoms during relapses are severe. It is therefore com-
prehensible that patients with a high symptom score at
inclusion also perceive severe relapses and prefer regular
dosing.
On-demand treatment is not a precise definition. The
term includes treatment of actual symptoms as in this
trial, treatment to prevent foreseeable symptoms, inter-
mittent therapy defined as regular intake of drugs for a
short period when needed, and threshold therapy in
which the patients adjust the medication down to a dose
and frequency that still maintains adequate control of
symptoms [5]. This trial, in which patients took one tablet
when needed to relieve symptoms, gives no information
about other on-demand dosage schedules. The intake of
approximately one tablet of Eso 20 every other day indi-
cates that the patients have taken the drugs as prescribed.
Conclusion
Overall satisfaction was significantly higher in patients
given esomeprazole 20 mg than in those given the pectin-
based raft-forming natural agent, and increased with age.
Most patients preferred on-demand treatment. The
minority who preferred continuous therapy had signifi-
cantly higher symptom scores at inclusion.
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Table 1: Characteristics of the subjects in the two treatment groups.
Patients' characteristics Eso20 PRA
Number of subjects 39 38
Male (no) 22 (56%) 21 (55%)
Age in years (mean) 47.8 (14.5) 46.2 (14.8)
BMI (mean) 26.2 (3.1) 25.7 (3.0)
Cups of coffee per day (mean) 3.0 (2.2) 3.3 (2.6)
Smokers (daily/past/never) (no) 9/12/18 10/16/12
Duration of reflux symptoms in years (mean) 8.0 (7.6) 8.0 (8.5)
Symptom score at inclusion (mean) 11.3 (3.9) 11.3 (4.1)
Degree of esophagitis (no)
- NERD 13 (33%) 15 (40%)
- Los Angeles Grade A 20 (51%) 17 (45%)
- Los Angeles Grade B 6 (15%) 6 (16%)
Hiatal hernia (no) 26 (67%) 24 (63%)
The groups were well balanced. The results are given as number of patients (proportion in brackets) or mean (standard deviation in brackets).
Eso20: Esomeprazole 20 mg.
PRA: Pectin-based Raft-forming Agent.
BMI: Body mass index.
NERD: Non erosive reflux disease.
Table 2: Effect and side effects in the two groups.
Effect and side effects Eso20 PRA Statistics
Overall satisfaction with the treatment (no) 36 (92%) 22 (58%) p = 0.001
Weeks of satisfactory relief (mean proportion) 89% (26) 62% (44) p = 0.008
Symptom score at the end of treatment (mean) 5.9 (3.4) 8.0 (4.4) p = 0.019
Preference for same drug after the trial (no) 33 (85%) 16 (42%) P < 0.001
Preference for regular treatment (no) 6 (15%) 6 (16%) ns (p = 1.00)
Diarrhoea (no) 1 (3%) 6 (16%) ns (p = 0.056)
Too many tablets (no) 2 (6%) 11 (29%) p = 0.006
Delayed onset of effect (no) 10 (26%) 4 (11%) ns (p = 0.14)
Rapid relapse of symptoms (no) 8 (21%) 18 (47%) p = 0.017
The results are given as number of patients (proportion in brackets) or mean (standard deviation in brackets).
Eso20: Esomeprazole 20 mg.
PRA: Pectin-based Raft-forming Agent.BMC Complementary and Alternative Medicine 2009, 9:3 http://www.biomedcentral.com/1472-6882/9/3
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